Association between leukotriene-modifying agents and suicide: what is the evidence?

@article{Schumock2011AssociationBL,
  title={Association between leukotriene-modifying agents and suicide: what is the evidence?},
  author={Glen T. Schumock and Todd A. Lee and Min Jae Joo and Robert J. Valuck and Leslie Thomas Stayner and Robert D. Gibbons},
  journal={Drug safety},
  year={2011},
  volume={34 7},
  pages={533-44}
}
The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LTMAs and suicidal behaviour. We conducted a literature search of MEDLINE, EMBASE and International Pharmaceutical Abstracts from 1995 to 2010 (inclusive) to identify pertinent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…